In the past year, there has been a high incidence of respiratory diseases in the country, and "influenza", "respiratory tract infection" and related drugs have been frequently searched. According to the results of the quantitative survey of Zhongkang consumer health, compared with 2023, in 2024, the respondents' health problems such as "respiratory tract and lung discomfort", "throat discomfort" and "ear and nose discomfort" will increase significantly, and the demand for respiratory system drugs and anti-infective drugs will increase.
In view of this health need, Dx&Vx recently announced that it will launch two new products in China, Bilitin (phencycular quinolium bromide nasal spray) and Fushanlong (ceftran neoamyl tablets), to provide more medication options for patients suffering from respiratory problems.
01
必立汀:
Fill the vacancy of out-of-hospital rhinitis medication
Since its launch in 2020, Bilitin has rapidly opened up the hospital market. According to the data of Zhongkang CMH, as an exclusive domestic variety, its sales have been rising for three years since its listing, and its sales will enter the TOP10 in the respiratory system-nasal medicine (chemical medicine) category of the grade hospital market in 2023.
The market sales scale of Bilitin - grade hospitals
Data source: Zhongkang CMH
Bilitin is the first self-developed non-hormonal, chemical class 1 new drug in the field of allergic rhinitis (AR) treatment in mainland China. The results of its phase III clinical study showed that the incidence of adverse reactions of phencycular quinolium bromide was comparable to that of the placebo group, and the incidence of each reaction was not higher than 2%, and all of them were mild. At the same time, there was no significant pharmacokinetic interaction with budesonide.
Professor Wang Xueyan, vice chairman of the Allergy Branch of the Chinese Medical Association, introduced in an interview with the Chinese Medical Information Herald that AR is one of the six major chronic diseases that the WHO focuses on prevention and treatment in the 21st century, and the current global prevalence rate is 10%-20%, ranking first among allergic diseases, and the incidence is increasing year by year, while the number of AR patients in mainland China has exceeded 300 million.
It should not be ignored that AR patients are often affected by a variety of comorbidities such as chronic sinusitis, asthma, headache, gastroesophageal reflux, etc., which cause serious economic and living burdens to patients' families and society. However, the current commonly used drugs for the treatment of AR in clinical practice have problems such as incomplete symptom improvement, slow onset of effect, and high incidence of adverse reactions with long-term use, and it is difficult for traditional treatment regimens to meet the needs of AR patients for rapid improvement of nasal symptoms, safety and effectiveness. Bilitin is a nasal spray form, which has the characteristics of local administration, convenient use and rapid onset, which fills the gap in the AR drug market to a certain extent and is a new choice for AR patients.
At present, phencycular quinedomium bromide has been included in the "Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition)" and other domestic and foreign AR treatment guidelines. It is reported that Bilitin also plans to apply for new indications such as post-cold rhinitis and chronic obstructive pulmonary disease, and the market potential is promising.
Dx&Vx revealed that in the future, Bilitin will further expand out-of-hospital channels and unite major chains to provide a more convenient drug experience for the majority of patients and benefit more AR patients.
02
Ryu Toyama:
The original research has entered the game, and the cephalosporin market will be reshuffled?
The high incidence of respiratory infections has also driven the demand for antimicrobials represented by cephalosporins.
According to Zhongkang CMH data, in the past five years, affected by centralized procurement and epidemic control, the overall sales scale of antimicrobial drugs in the grade hospital market has shown a downward trend. In terms of pharmacy terminals, the sales scale of systemic antimicrobial drugs will exceed 15.5 billion yuan in 2023, a year-on-year increase of 2.3%, of which cephalosporins account for nearly 30% of the market share.
Focusing on the ceftran neoamyl category, in 2023, the sales of terminal hospitals and pharmacies will exceed 20 million yuan, and tablets will occupy a high share in terms of dosage forms. Overall, although the current market scale is not large, it has gradually come out of the shadow of epidemic control, and the market space needs to be tapped. At present, the mainstream manufacturers of ceftren neopentyl ester market include Guangdong Bozhou Pharmaceutical and Qilu Anti Pharmaceutical, and Fushanlong has entered the domestic market as an original product, which will inject new vitality into the market.
Cefteram neoamyl ester is a third-generation oral cephalosporin, which has the characteristics of strong antibacterial activity, wide antibacterial spectrum, high enzyme resistance and low toxicity to humans compared with the first and second generations.
Data source: Enterprise test results
Clinical trials have shown that Fushanlong has a strong bactericidal ability against common pathogens of respiratory tract infections and has a wide range of indications, and can be used in combination with azithromycin and erythromycin. It can be expected that after Fushanlong is listed in the domestic market, it will not only bring high-quality products to patients, but also provide chain operators with more options for related drugs, and the market space is broad.
Since entering the Chinese market in 1996, Dx&Vx has continued to enrich its product line to meet the needs of more patients in multiple dimensions.
On May 9th, Dx&Vx will officially hold a new product launch conference in Wuhan to promote Bilitin and Fushanlong to the Chinese market and provide patients with better and more convenient health solutions.
At the meeting, Dx&Vx will also release the SCSS system, which is a digital management software developed based on SaaS cloud technology, aiming to help grassroots medical institutions build a digital operation system.
The SCSS system can provide prescription management, inventory management, sales management and other services for primary medical institutions, and at the same time realize intelligent distribution through the function of air pharmacy to reduce storage costs. In addition, a knowledge base of Korean and American experts has been grafted to provide academic support for doctors. The SCSS system empowers grassroots medical institutions through multi-dimensional diagnosis and treatment platforms, supply chain platforms, doctor gas stations, and point malls, helping them achieve refined management and efficient operation.
— END —